The pros and cons of the PCC staging system to guide surgical resectability and prognosis

Pei Liu, Yinghui Song, Kashif Shakoor, Chuang Peng, Sulai LiuJournal of Cancer 2022 · DOI

TL;DR

This review critically examines existing staging systems for perihilar cholangiocarcinoma (PCC), a complex bile duct cancer. It highlights the limitations of current systems in accurately guiding surgical decisions and predicting patient outcomes, emphasizing the need for a more comprehensive approach.

What Problem Does This Paper Address?

Perihilar cholangiocarcinoma (PCC), also known as Klatskin tumor, is a challenging malignancy originating from the bile ducts near the liver. A major hurdle in treating PCC is the lack of a universally accepted staging system that accurately predicts surgical resectability and patient prognosis. This ambiguity leads to difficulties in treatment planning, comparing patient outcomes across different institutions, and ultimately, improving survival rates, which remain low. The paper aims to dissect the strengths and weaknesses of various existing staging systems to inform better clinical decision-making.

Methods

This paper is a comprehensive review of existing staging systems for perihilar cholangiocarcinoma. The authors systematically analyze and compare several prominent classification methods, including:

  • Bismuth-Corlette classification: Based on the anatomical location of the tumor within the bile duct confluence.
  • AJCC/UICC TNM staging: A widely used system that considers tumor size (T), lymph node involvement (N), and distant metastasis (M).
  • Modified T staging (MSKCC T staging): Focuses on tumor invasion into the bile duct, portal vein, and liver atrophy.
  • Gazzaniga staging: Evaluates bile duct and vascular invasion.
  • JSBS staging: A system developed by the Japanese Society for Biliary Surgery.
  • Mayo staging: A clinically based system that incorporates tumor characteristics, vascular invasion, lymph node status, peritoneal metastasis, and CA19-9 levels.

The review synthesizes findings from numerous studies to evaluate each system's pros and cons regarding its ability to guide surgical resectability assessment and predict prognosis and survival.

Datasets

Not discussed in the paper. The paper is a review and does not present new experimental data or datasets.

Key Insights and Ideas

  • No single perfect system: The most significant takeaway is that no current staging system for PCC is ideal. Each has strengths but also critical limitations, making a comprehensive approach essential.
  • Resectability vs. Prognosis: Different staging systems excel at different aspects. Some are better for guiding surgical approaches (e.g., Bismuth-Corlette), while others are more predictive of survival (e.g., Mayo staging).
  • TNM limitations: While widely used, the AJCC/UICC TNM staging system is criticized for not adequately incorporating factors crucial for PCC prognosis, such as microvascular invasion and peripheral nerve invasion. Its prognostic ability for PCC remains suboptimal.
  • Bismuth-Corlette's anatomical focus: This system is valuable for surgical planning due to its clear anatomical basis, but it offers poor evaluation of resectability and prognosis on its own.
  • Mayo staging's prognostic power: The Mayo staging system shows promise for predicting patient survival, especially in Asian populations, but its utility in assessing resectability pre-operatively is less clear.
  • The complexity of hilar anatomy: The intricate vascular and biliary anatomy at the hepatic hilum contributes significantly to the difficulty of surgical resection and the limitations of staging systems.

Key Results

The paper does not present quantitative results from new experiments but rather synthesizes findings from existing literature. Key qualitative findings include:

  • Bismuth-Corlette: Useful for guiding surgical methods but poor for evaluating resectability and prognosis.
  • TNM Staging: Widely used as a basis for cancer treatment, but with poor prediction for postoperative survival time. The 8th edition has attempted improvements but still faces limitations.
  • MSKCC T Staging: Offers good evaluation of tumor resectability but has limited prognostic significance for postoperative patients.
  • Gazzaniga Staging: Easy to understand but has limited significance for selecting preoperative surgical methods and evaluating prognosis.
  • JSBS Staging: Considered better for patient prognosis than TNM staging in some comparative studies, but its evaluation of unresectable tumors is limited.
  • Mayo Staging: A good predictor of survival in unresectable masses, but its value in preoperative resectability assessment is not well-established.

Limitations and Future Work

Limitations:

  • Lack of a unified system: The primary limitation is the absence of a single, comprehensive staging system that effectively guides both surgical resectability and prognosis prediction for PCC.
  • System-specific weaknesses: Each discussed system has inherent flaws, such as not considering all relevant prognostic factors (e.g., TNM missing microvascular invasion) or being difficult to apply universally (e.g., anatomical variations affecting Bismuth-Corlette).
  • Single-center data: Some promising systems, like Mayo staging, are based on single-center data and require broader validation.
  • Difficulty in distinguishing subtypes: It can be challenging to differentiate intrahepatic cholangiocarcinoma from PCC pre-operatively, complicating staging.

Future Work:

The authors implicitly suggest the need for:

  • Development of a more integrated staging system: One that combines anatomical, pathological, and clinical factors to provide a more holistic assessment of resectability and prognosis.
  • Further validation of promising systems: Particularly for systems like Mayo staging, broader multi-center validation is crucial.
  • Incorporation of novel biomarkers: Future staging systems might benefit from including molecular or genetic markers to enhance prognostic accuracy.
  • Continued research into treatment advancements: As new treatments emerge (e.g., immunotherapy), staging systems will need to adapt to guide their application.

Summary updated

Abstract

Perihilar cholangiocarcinoma (PCC) is a malignant mass originating from the bile ducts. There is currently no unified treatment plan, and there are various treatment methods applied in clinical practice, as well as several different staging and typing systems to guide resectability, prognosis and survival prediction. The choice of treatment for PCC is closely related to the stage of the tumor. Accurate preoperative staging is necessary for correct resectability assessment and the selection of a reasonable treatment plan and surgical method; similarly, accurate postoperative pathological staging is necessary to guide further treatment and judgment of the patient's prognosis. A universally accepted staging system facilitates the comparison of cases between different centers, but there is much debate about the classification and staging of PCC. At present, the existing staging systems include the Bismuth-Corlette classification, AJCC/UICC TNM staging, modified T staging, Gazzaniga staging, JSBS staging, and Mayo staging. Each system has advantages, but there is no comprehensive guide for tumor resectability, prognosis, and survival. In this paper, the pros and cons of the different systems for staging PCC in terms of resectability, prognosis and survival prediction are discussed.
BibTeX
@article{liu2022pros,
  author = {Pei Liu and Yinghui Song and Kashif Shakoor and Chuang Peng and Sulai Liu},
  title = {{The pros and cons of the PCC staging system to guide surgical resectability and prognosis}},
  journal = {Journal of Cancer},
  year = {2022},
  doi = {10.7150/jca.76696},
}
Figure